GLPwatch
In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
Ann Intern Med · 2024
Last updated 2026-05-28In a study of 17,604 adults with overweight or obesity and cardiovascular disease but without diabetes, those taking semaglutide had a 20% lower risk of major cardiovascular events over an average of 40 months compared to those taking a placebo.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2024 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.20 |
| NIH percentile | 13 |
| Molecules | semaglutide |
| Conditions studied | Obesity, Cardiovascular Risk Reduction |
Abstract
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. N Engl J Med. 2023;389:2221-2232. 37952131.
Verbatim abstract via PubMed 38437690 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.